Product image of Zolgensma (Onasemnogene Abeparvovec) supplied by GNH India

Zolgensma

Active Ingredient:
Onasemnogene Abeparvovec
Origin:
EU

Zolgensma (Onasemnogene Abeparvovec)

Zolgensma (onasemnogene abeparvovec) is a gene therapy for spinal muscular atrophy (SMA) in pediatric patients. Administered via intravenous infusion, it replaces the faulty SMN1 gene. This overview covers key facts for informed decision-making.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zolgensma is a gene therapy designed to address spinal muscular atrophy (SMA), a genetic disorder affecting motor neurons. It is indicated for pediatric patients with confirmed biallelic mutations in the SMN1 gene. By delivering a functional copy of the SMN1 gene, it aims to improve motor function and survival outcomes. Families often seek this treatment to manage SMA progression in infants.

Side Effects

  • After administration, Zolgensma works at the genetic level to produce the SMN protein, which supports motor neuron health. Patients may experience gradual improvements in muscle strength and motor skills over time. The therapy’s effects are monitored through clinical evaluations rather than immediate symptomatic relief. Individual responses vary based on baseline disease severity.

Precautions & Warnings

  • Zolgensma is administered in a clinical setting by healthcare professionals trained in gene therapy. Patients require close monitoring for potential adverse reactions, including liver function changes and thrombocytopenia. Pre-treatment screening ensures eligibility, and post-treatment follow-ups track progress. Avoid exposing the product to extreme temperatures during transport.

Avoid Interactions

  • No formal drug interaction studies have been conducted with Zolgensma. However, caution is advised when combining with medications that affect liver enzymes, such as certain anticonvulsants or immunosuppressants. Live vaccines should be avoided for 6 months post-treatment due to potential immune response interference. Always disclose all medications to the treating physician.

Frequently Asked Questions

Zolgensma is a gene therapy for spinal muscular atrophy (SMA) caused by mutations in the SMN1 gene, typically in pediatric patients.

It is given as a single-dose intravenous infusion in a healthcare setting, following specific preparation and monitoring protocols.

Potential side effects include elevated liver enzymes and low platelet counts, which are monitored closely after treatment.

Zolgensma is primarily indicated for pediatric patients with SMA; adult eligibility depends on specific clinical criteria.

The infusion itself takes about 60 minutes, but the entire process includes pre-screening, administration, and post-treatment monitoring.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Onasemnogene Abeparvovec

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT